West Virginia Clinical Trials Report — June 2026

For West Virginians considering participation in clinical research, June 2026 presents a dynamic landscape of new opportunities, particularly in major drug development, but also a critical window for trials nearing their conclusion. Across the state, 321 clinical trials are actively recruiting across 24 cities and 158 research sites, offering diverse avenues for contribution to medical science.

Time is Running Out for 14 West Virginia Trials

A total of 14 clinical trials in West Virginia are slated to close within the next 90 days, meaning interested individuals should act quickly to explore these opportunities. Among these, 3 trials are still accepting healthy volunteers, providing a chance to contribute to medical understanding without a specific health condition. These closing trials cover a range of conditions, highlighting the urgent need for participation in these specific areas of research:

• Atopic dermatitis
• Atrial fibrillation
• Bleeding
• Cervical carcinoma
• Chronic granulomatous disease (CGD)
• Chronic kidney disease; iron deficiency anemia
• Chronic migraine in children
• Endocrine system diseases
• Exophthalmos
• Eye diseases

If you or someone you know lives with one of these conditions, or if you are a healthy volunteer looking to participate, now is the time to investigate these trials before enrollment windows close.

A Surge in New Research: June Brings 9 New Trials

This month marks a significant expansion in West Virginia's clinical research landscape, with 9 new trials opening for enrollment. This is a substantial increase compared to the single trial that opened in May 2026, indicating a renewed focus on the state for groundbreaking studies. These new initiatives include several major Phase 2 and Phase 3 drug trials from prominent sponsors, offering access to cutting-edge treatments for widespread health challenges.

Major Pharmaceutical Trials Lead the Way

AstraZeneca and Kallyope Inc. are sponsoring several notable Phase 3 trials this month, focusing on conditions like obesity, type 2 diabetes, and migraine. These studies represent significant investments in new treatments and offer participants the chance to be among the first to access investigational therapies.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management and type 2 diabetes.
• Another significant Phase 3 trial from AstraZeneca is NCT07662109, which is "A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus." This study plans for 2,000 participants to assess a combination therapy for type 2 diabetes.
• Also from AstraZeneca, NCT07662213 is "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus." This Phase 3 trial will enroll 1,200 participants.
• For individuals experiencing migraines, Kallyope Inc. is sponsoring NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This Phase 3 trial is designed for 1,800 participants.
• Kallyope Inc. is also leading NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," a Phase 3 study for 1,000 participants.
• Additionally, Evommune, Inc. is sponsoring NCT07616128, "Study of EVO756 in Adults With Migraine," a Phase 2 trial for 330 participants.

Diverse Conditions and Interventions

The 9 new trials opening this month address a variety of health conditions, with a strong emphasis on metabolic health and neurological disorders. The most common conditions targeted by these new studies include:

• Type 2 diabetes mellitus (3 trials)
• Migraine (3 trials)
• Gastrointestinal lesions
• Irritable bowel syndrome (IBS-C)
• Microwave ablation
• Pancreatic lesion
• RFA (Radiofrequency Ablation)
• Ablation techniques
• Weight management

In terms of the types of interventions, drug trials account for the majority, with 6 new studies. Other new research includes a behavioral trial, a device trial, and another classified as 'other,' showcasing a broad approach to medical advancement.

Morgantown Emerges as a Key Research Hub

West Virginia's clinical research efforts are broadly distributed, with 321 trials recruiting across 24 cities. This month, the city of Morgantown stands out as a significant center for new research, hosting 7 of the 9 newly opened trials. This concentration of new studies in Morgantown, alongside single new trials in Crab Orchard and Kingwood, indicates a strong focus on the state's larger metropolitan areas for clinical investigations. This geographic distribution helps ensure that residents in various regions of West Virginia have access to cutting-edge research opportunities.

Participation Opportunities: Focus on Older Adults

While none of the 9 new trials specifically seek healthy volunteers, there are still 23 existing trials statewide that are actively recruiting healthy participants. This provides numerous avenues for individuals without a specific medical condition to contribute to medical research. Eligibility criteria for the new trials are inclusive, with 8 of them actively seeking older adults. No new trials are exclusively for children, or for female-only or male-only participants this month, ensuring broad demographic representation in the research.

Academic institutions, particularly West Virginia University, continue to play a vital role in the state's research ecosystem, sponsoring 3 of the new trials. Industry sponsors like AstraZeneca, Kallyope Inc., and Evommune, Inc. are also driving significant research efforts, sponsoring 6 of the new trials.

As we move further into June, the focus will remain on the ongoing enrollment in these significant Phase 2 and 3 trials, and the exploration of new treatments and diagnostic methods for a broad spectrum of health challenges across West Virginia.